Results 191 to 200 of about 5,708 (209)

A clinical phase I study of an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03

Vaccine, 2015
We conducted a phase I clinical trial of a cell culture-derived AS03-adjuvanted influenza vaccine containing HA antigen (A/Indonesia/05/2005(H5N1)/PR8-IBCDC-RG2) derived from EB66 cells (KD-295).Healthy male adult volunteers (20-40 years old, N=60) enrolled in the study were divided into 3 groups, the MA group (3.8 μg of HA+AS03), HA group (7.5 μg of ...
Takeshi, Naruse, Tadashi, Fukuda, Tetsuro, Tanabe, Munetaka, Ichikawa, Yoshiaki, Oda, Shinji, Tochihara, Kazuhiko, Kimachi, Yoichiro, Kino, Kohji, Ueda   +8 more
openaire   +2 more sources

Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine

Vaccine, 2013
Anaphylaxis after trivalent influenza vaccination is typically reported at a rate of
Isabelle, Rouleau, Gaston, De Serres, Jean Philippe, Drolet, Danuta M, Skowronski, Manale, Ouakki, Eveline, Toth, Monique, Landry, Suzanne, Ménard, Rémi, Gagnon   +8 more
openaire   +2 more sources

Topic: AS03-Health Economics & Outcome Research/AS03b-Patient-reported outcomes

Leukemia Research, 2021
J. Dubow, A. Guerci, E. Gyan, A. Dupuis-Sireva   +3 more
  +4 more sources

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity

Vaccine, 2011
AS03 is an Adjuvant System (AS) containing α-tocopherol and squalene in an oil-in-water (o/w) emulsion. AS03 has been considered for the development of pandemic and seasonal influenza vaccines. Key features of AS03's mode of action were investigated in vivo in mice and ex vivo in human cells.
Sandra, Morel, Arnaud, Didierlaurent, Patricia, Bourguignon, Sophie, Delhaye, Benoît, Baras, Valérie, Jacob, Camille, Planty, Abdelatif, Elouahabi, Pol, Harvengt, Harald, Carlsen, Anders, Kielland, Patrick, Chomez, Nathalie, Garçon, Marcelle, Van Mechelen   +13 more
openaire   +2 more sources

An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines

Vaccine, 2019
Although oil-in-water adjuvants improve pandemic influenza vaccine efficacy, AS03 versus MF59 adjuvant comparisons in A(H1N1)pdm09 pandemic vaccines are lacking.We conducted an indirect-comparison meta-analysis extracting published data from randomised controlled trials in literature databases (01/01/2009-09/09/2018), evaluating immunogenicity and ...
Michael I. Hauser, David J. Muscatello, Annabel C.Y. Soh, Dominic E. Dwyer, Robin M. Turner   +4 more
openaire   +2 more sources

Topic: AS03-Health Economics & Outcome Research/AS03a-Cost of care

Leukemia Research, 2021
A.M. Zeidan, N. Joshi, H. Kale, W.-J. Wang, S. Corman, K. Hill, T. Salimi, R. Epstein   +7 more
openaire   +2 more sources

Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6–35 months

Vaccine, 2010
We report on the evaluation of the immunogenicity and reactogenicity/safety of AS03-adjuvanted vaccine against pandemic influenza A/H1N1/2009 in young children. In this open-label, randomized study, 157 healthy children aged 6-35 months received two doses (21 days apart) of split-virion inactivated A/California/7/2009 H1N1 vaccine containing either (i)
Alfonso, Carmona, Félix, Omeñaca, Juan C, Tejedor, Jose M, Merino, Tejaswini, Vaman, Ilse, Dieussaert, Paul, Gillard, Javier, Arístegui   +7 more
openaire   +2 more sources

Evaluation of the Performance Benefits of the Winglet Active Trailing Edge in AS03

2015
An engineering demonstrator of the winglet active trailing edge (WATE) concept was manufactured by AS03 partners in SARISTU. In parallel, simulation activities were used to investigate the performance benefits of active winglets. A study made by AS03 partners (led by AGI-G) assessed the capacity of the WATE—with a suitably designed controller—to ...
openaire   +1 more source

Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study

EClinicalMedicine, 2023
Gustavo H. Dayan, N. Rouphael, Stephen R. Walsh, Aiying Chen, N. Grunenberg, Mary A Allen, Johannes Antony, A. Bhate, T. Beresnev, M. Bonaparte, Médéric Celle, M. Ceregido, Lawrence Corey, Bo Fu, M. Grillet, M. keshtkar-Jahromi, M. Juraska, J. J. Kee, S. Kaali, M. Koutsoukos, R. Masotti, Nelson L. Michael, K. Neuzil, H. Reynales, M. Robb, Akiyoshi Uchiyama, Fredrick Sawe, Lode Schuerman, Rajeev Shrestha, T. Tong, J. Treanor, C. Diazgranados, R. Chicz, S. Gurunathan, Stephen Savarino, Saranya Sridhar, Karina Abalos, Michael R. Adams, Mohamed Allaw, Naveena Aloysia, J. Amuasi, N. Ansah, Kwaku Poku Asante, D. Benkeser, Aude Berge, Thomas Breuer, Liz Briesemeister, Gail B Broder, Alberto Cadena Bonfanti, Cornell Calinescu, Richard Canter, Jaime Augusto Carrillo, D. Chansinghakul, F. Coux, Chandan Das, Matthew Davies, Louis Devlin, Michael P. Fay, D. Follmann, Carina Frago, Hiroyuki Fukase, Agnes Garinga, P. Gilbert, Claudia Gonzalez, M. A. Granados, Cathy Greiwe, Lea Guillery, Jessicalee Hall, J. Henderson, Ying Huang, Kathy Hudzina, J. Hural, M. Hutchens, M. Jain, William Jennings, Piush Kanodia, M. Kimmel, William Kirby, Nitin Khandelwal, James Kopp, Chalit Kosolsak, Jim Kublin, D. Kukian, J. Kushwaha, Thelma M. Laot, Eduardo López-Medina, Hugo Macareno Arroyo, Stephanie Mamod, S. Mangarule, Troy Martin, L. Menard, Sandra Mendoza, Robert Meyer, Randle Middleton, Jill Miracle, K. Mizuyama, Satyajit Mohapatra, Catherine Moreau, Linda Murray, Shinya Nagamatsu, Joseph L. Newberg, Fernando Noriega, Paul J. Nugent, Michele Peake-Andrasik, David Pekala, Penny Peng, Marie-Laure Py, S. Ramirez, Chinthaparthi Prabhakar Reddy, Michelle Reynolds, Enrique Rivas, N. Sater, Jinen Shah, Lawrence D Sher, Silva Sieger, Chandramani Singh, Veer Bahadur Singh, Nuchra Sirisuphmitr, T. Starkey, Kazuo Suzuki, D. Tamrakar, Cayce Tangemen, Fernanda Tavares Da-Silva, David Taylor, Leslie Tharenos, T. A. Wartel, Elodie Zaworski, Nianxian Zhang   +127 more
semanticscholar   +1 more source

Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data

Expert Opinion on Biological Therapy, 2009
Universal and timely administration of a prepandemic vaccine is considered to be one of the most effective measures to reduce the incidence of pandemic influenza infection and consequently its morbidity and mortality.To provide the reader with basic insights into influenza virus infections, the threat of a pandemic and the challenges it poses for ...
openaire   +2 more sources